THE generics price war is
continuing to hot up, with an
unnamed atorvastatin sponsor
having initiated a 25% price cut on
the product effective from the
beiginning of December.
Both Alphapharm and Ranbaxy
have distanced themselves from
the move which under the price
disclosure arrangements will affect
all generic Lipitor suppliers.
Alphapharm issued a statement
on Saturday in which it “states
categorically that it is not
responsible for the price cut.
“Alphapharm is interested to
understand the logic and rational
for the cut from the sponsor that
initiated it,” the company ...
The above snippet is the first part of an article sent to subscribers in Pharmacy Daily's issue from 16 Jul 12
Established in 2007, Pharmacy Daily is Australia's leading pharmacy industry publication, and is sent as a free subscription to people across the industry as a PDF newsletter every weekday.
To sign up for a free subscription, click on the button at right.
